We spoke with Dr. Gerald Falchook about the first human study of a first-in-class molecule, fatty acid synthase inhibitor known as TVB-2640 for advanced solid tumors.
Gynecological Cancer Targets
A new international study has identified 12 new genetic variants associated with an increased risk of developing epithelial ovarian cancer.
We spoke with Dr. G. Larry Maxwell, Chair of the Department of Obstetrics and Gynecology at Inova Fairfax Hospital, about a potential new biomarker to help distinguish metastatic versus nonmetastatic disease in endometrial cancer.
Researchers at the NYU Langone Medical Center’s Perlmutter Cancer Center have discovered multiple somatic mutations and copy-number alterations in UCS tumors that offer expanded therapeutic options.
We spoke with Dr. Elizabeth Swisher about the ARIEL2 trial and the role of rucaparib in ovarian cancer.
Researchers have identified a protein that may respond to PI3K/mTOR inhibitors for patients with a specific type of uterine sarcoma.
California researchers are now suggesting that analyzing copies of genes may point to new treatments for ovarian cancer as well as for other tumor types. The researchers contend that targetable genetic changes in tumors should not be limited to mutations.
The FDA granted accelerated approval to rucaparib (Rubraca), a PARP inhibitor, for the treatment of women with deleterious BRCA mutation-associated ovarian cancer.
A new study is suggesting that combining BET inhibitors with other agents targeting protein kinases might make them more effective in treating cancer.
Researchers are hoping that adding a checkpoint inhibitor to the treatment armamentarium may help improve outcomes in patients with locally advanced or metastatic disease epithelial ovarian cancer.